News | January 21, 2026
Senores Pharmaceuticals reports stellar Q3 FY26 growth; PAT surges 105%
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
Experts warn that illegal products may be fake, contaminated, incorrectly dosed, or contain powerful unlisted ingredients
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
NUFYMCO BLA has been approved by the USFDA
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
